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Background
Recombinant activated coagulation factor VII (rFVIIa),
structurally nearly identical to human plasma-derived
coagulation factor VIIa, is thought to promote haemostasis
by activating coagulation cascade, and converting pro-
thrombin to thrombin. Initially, recombinant factor VIIa
was approved for the treatment of bleeding in patients with
haemophilia A or B who have inhibiting antibodies to
coagulation factor VIII or IX. Later, indications were
broadened to include the treatment of bleeding events, and
the prevention of bleeding episodes related to surgical or
invasive procedures, in patients with congenital or acquired
haemophilia, factor VII deficiency, or Glanzmann’s
thrombasthenia. However, in recent years, rFVIIa has been
used, on an off-label basis, to act as a pro-haemostatic
agent in patients with a pre-existent normal coagulation
system who experienced massive or uncontrolled bleeding.
In the past decade, the use of rFVIIa for the approved
haemophilia indications remained stable over time,
whereas the off-label prescriptions increased: according to
the recent surveys, more than 90% of rFVIIa prescriptions
are for off-label indications [1, 2]. Given the physiology of
activated factor VII, a potential adverse event of concern is
the risk of thromboembolic complications.
Summary
Data from 35 randomized clinical trials of off-label indi-
cations for rFVIIa versus placebo (26 studies involving
patients and nine studies involving healthy volunteers)
were analysed to determine the frequency of thromboem-
bolic events [3]. Most of the clinical trials were Novo
Nordisk-sponsored studies (29 vs. 6 investigator-initiated
trials). The data were pooled and the rates of thrombo-
embolic events were calculated in rFVIIa and placebo
groups. Odds ratios for thromboembolic events, adjusted
for age, type of bleeding, type of adverse event and dose of
rFVIIa, were calculated with the use of logistic regression.
A total of 4,468 subjects (4,119 patients and 349 healthy
volunteers) were included. Most of them were patients with
spontaneous central nervous system bleeding (31.3%),
followed by bleeding due to advanced liver disease
(27.8%), trauma (18.7%) cardiac surgery (6%) or spinal
surgery (1.1%) and bleeding from other causes (5.1%).
Healthy volunteers were 349 (7.8% of the subjects).
When the results were adjusted for age and type of
bleeding, there was no significant difference (p = 0.16) in
the rate of thromboembolic events between patients who
received rFVIIa (10.2%) and those who received placebo
(8.7%). Considering only arterial thrombosis as outcome,
the rates of thromboembolic events were higher among
those who received rFVIIa than among those who received
placebo (5.5 vs. 3.2%, p = 0.003). Among patients who
were 65 years of age or older, the risk of arterial throm-
boembolic events was higher for those taking rFVIIa
compared to placebo group (OR 2.43, 95% CI 1.34–4.41).
The rate of venous thromboembolic events was 5.3%
among patients who received treatment, as compared with
5.7% among patients in the placebo group with no signif-
icant statistical difference (p = 0.61). The rate of
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thromboembolic events in 349 healthy volunteers was the
same both among those who received rFVIIa (2/232) and
among who received placebo (1/117).
Strength of the study
– The use of rFVIIa on an off-label basis to treat life-
threatening bleeding has been constantly increasing,
thus the evaluation of the risk of thrombotic compli-
cations is relevant.
– It is the first analysis from randomized placebo-
controlled clinical trials focused only on the thrombo-
embolic adverse events occurring in patients adminis-
trated off-label rVIIa.
Weakness of the study
– The individual study samples were relatively small, and
there was clinical heterogeneity with different indica-
tions for rVIIa treatment (e.g., central nervous system
bleeding, bleeding from liver disease, trauma, and other
causes).
Question marks
– The statistical models used to pool the data are not
clear. In the abstract, it is mentioned the use of random-
effects models while it is not described in the statistical
analysis paragraph of the paper.
– The number of the total thromboembolic events
reported in the abstract (498) and in the text (401)
does not match.
Sponsorship
– The study was funded by Novo Nordisk, the Novo
Seven producer; however, although the results were
negative for the Company, the authors decided to
publish the data.
Clinical bottomline
Many consider rFVIIa to be the ‘‘magic bullet’’ of haemo-
stasis and believe that rFVIIa can cure all bleeding. Even
without considering the effectiveness of off-label use of
rVIIa, safety is a big concern. When rFVIIa is used on an
off-label basis to treat life-threatening bleeding, it is man-
datory to take into account the increased risk of thrombotic
complications, particularly among older patients.
Conflict of interest None.
References
1. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M (2005)
A multicenter assessment of recombinant factor VIIa off-label
usage: clinical experiences and associated outcomes. Transfusion.
45:1434–1442
2. Magnetti S, Oinonen M, Matuszewski KA (2007) An evaluation of
off-label use of recombinant activated human factor VII (Novo-
Seven): patient characteristics, utilization trends, and outcomes
from an electronic database of US academic health centers. Pharm
Ther. 32:218–230
3. Levi M, Levy JH, Andersen HF, Truloff D (2010) Safety of
Recombinant Activated Factor VII in Randomized Clinical Trials.
N Engl J Med 363:1791–1800
262 Intern Emerg Med (2011) 6:261–262
123
